Bristol Myers Squibb Acquires Radiopharma Company RayzeBio
Bristol Myers Squibb has added a premier radiopharmaceutical platform to its portfolio with the acquisition of RayzeBio, a radiopharmaceutical therapeutics
Read moreBristol Myers Squibb has added a premier radiopharmaceutical platform to its portfolio with the acquisition of RayzeBio, a radiopharmaceutical therapeutics
Read moreAstraZeneca announced it has agreed to acquire Gracell Biotechnologies Inc, which is set to advance its cell therapy portfolio across
Read moreIn a significant development for the fight against advanced small cell lung cancer (SCLC), the U.S. Food and Drug Administration
Read moreAbbVie is set to acquire ImmunoGen in a $10.1B deal which encompasses ImmunoGen’s first-in-class antibody-drug conjugate (ADC) cancer treatment ELAHERE®
Read moreBoehringer Ingelheim has confirmed the acquisition of T3 Pharmaceuticals AG, a Swiss clinical-stage biotech company thereby expanding its immuno-oncology portfolio.
Read moreVANFLYTA® (quizartinib) is now the first FLT3 inhibitor approved in the European Union (EU) specifically for the treatment of patients
Read moreElly Lilly announced plans to acquire POINT Biopharma, with the strategic move set to boost Lilly’s oncology capabilities with next-generation
Read moreOrano Med, a clinical-stage biotechnology company that develops the next generation of targeted therapies against cancer using the unique properties
Read moreULTRAMIC® ceramic heaters from Watlow® are engineered for thermal applications where the high performance of advanced ceramic heaters is required
Read moreEisai Co., Ltd. revealed that it has partnered with Bliss Biopharmaceutical (Hangzhou) Co., Ltd. to develop BB-1701, an antibody-drug conjugate
Read more